We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 354

Moneytree report shows increased life sciences investments in Q1 2011

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 19 2011

According to a PricewaterhouseCoopers report on venture capital investments, although fewer deals occurred in the first quarter of 2011 (Q1 2011) as compared to the last quarter of 2010, investment activity increased 5 percent overall

Biotech secures $5.3 million for immunosuppressant drug research

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • April 18 2013

San Francisco-based startup, Nurix, Inc., which reportedly develops T-cellspecific immunosuppressants used to treat autoimmune diseases such as

Agilent Technologies acquires BIOCIUS Life Sciences

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • March 10 2011

California-based Agilent Technologies has announced the acquisition of BIOCIUS Life Sciences, a Massachusetts-based company that developed a spectrometry device, enabling "researchers to gain a fuller understanding of a drug's biochemical properties, including potential liabilities in drug interactions

FDA schedules public hearing on biosimilar guidance documents

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • March 15 2012

The Food and Drug Administration (FDA) has scheduled a May 11, 2012, public hearing in Silver Spring, Maryland, “to obtain input on recently issued draft guidances relating to the development of biosimilar products.”

French company prevails in dispute with FDA over drug-classification ruling

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • October 3 2012

A federal court in the District of Columbia has determined that the Food and Drug Administration (FDA) erred when it classified a combination drug-device product as primarily a drug, thus subjecting its French manufacturer to more burdensome regulatory requirements

U.S. intervenes in False Claims Act suit against biotech company

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • April 4 2013

The U.S. government has intervened in part of a False Claims Act (FCA) lawsuit against Agave BioSystems, a biotechnology-based small business with

Biopharma co. seeks $90 million for tainted raw material from China

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 3 2012

A biopharmaceutical company has sued companies in its supply chain, alleging they were negligent or vicariously liable for obtaining from China a raw material, contaminated with beef broth and avian products, for use in the creation of a bacterial master cell bank for the production of a biologic drug that will be used in patients with acute spinal cord injury

PROLOR Biotech to raise $75 million for clinical trials on growth hormones

  • Shook Hardy & Bacon LLP
  • -
  • Israel, USA
  • -
  • April 19 2012

In an April 6, 2012, filing with the U.S. Securities and Exchange Commission, Israel-based PROLOR Biotech, Inc. has registered the sale of common stock on the American Stock Exchange in an amount not to exceed $75 million

Financial group analyzes M&A deals in biotech and medical device industries

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • June 16 2011

According to an SVP Financial Group report, contrary to conventional wisdom, biotech exits occur faster than device exits and have lower, but solid, multiples on invested capital

Changes in biotech investments reflect concerns over health-care costs

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • November 17 2011

While venture capitalists are reportedly investing less in early-stage biotechnology and medical devices, some of their dollars are apparently finding their way to companies that offer ways to reduce health care costs, such as those in the information technology sector